Evidence map›Paper›PMID 35604675›Full record

ArticleMedical mycology2022

Investigation of the value of precipitins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with a positive marker for Aspergillus species.

A P Bellanger, S Lallemand, A Tumasyan Horikian, J C Navellou, C Barrera, A Rouzet, E Scherer, G Reboux, G Piton, L Millon

Open access · bronzeAbstract read
In one paragraph

Article in Medical mycology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Pathogens (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A P BellangerDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.ORCID 0000-0003-4144-476X
S LallemandDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.
A Tumasyan HorikianDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.
J C NavellouIntensive Medical Care Unit, Regional Hospital of Besancon, Besancon, France.
C BarreraDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.
A RouzetDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.
E SchererDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.
G RebouxDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.ORCID 0000-0002-7923-0858
G PitonIntensive Medical Care Unit, Regional Hospital of Besancon, Besancon, France.
L MillonDepartment of Parasitology-Mycology, University Hospital of Besançon, Besancon, France.
Centre Hospitalier Universitaire de Besançon · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although a high prevalence of COVID-19-associated pulmonary aspergillosis has been reported, it is still difficult to distinguish between colonization with Aspergillus fumigatus and infection. Concomitantly, similarities between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hypersensitivity pneumonitis were suggested. The objective of this study was to investigate retrospectively if precipitin assays targeting A. fumigatus could have been useful in the management of SARS-CoV-2 patients hospitalized in an Intensive Care Unit (ICU) in 2020. SARS-CoV-2 ICU patients were screened for Aspergillus co-infection using biomarkers (galactomannan antigen, qPCR) and culture of respiratory samples (tracheal aspirates and bronchoalveolar lavage). For all these patients, clinical data, ICU characteristics and microbial results were collected. Electrosyneresis assays were performed using commercial A. fumigatus somatic and metabolic antigens. ELISA were performed using in-house A. fumigatus purified antigen and recombinant antigens.Our study population consisted of 65 predominantly male patients, with a median ICU stay of 22 days, and a global survival rate of 62%. Thirty-five patients had at least one positive marker for Aspergillus species detection. The number of arcs obtained by electrosyneresis using the somatic A. fumigatus antigen was significantly higher for these 35 SARS-CoV-2 ICU patients (P 0.01, Welch's t-test). Our study showed that SARS-CoV-2 ICU patients with a positive marker for Aspergillus species detection more often presented precipitins towards A. fumigatus. Serology assays could be an additional tool to assess the clinical relevance of the Aspergillus species in respiratory samples of SARS-CoV-2 ICU patients. LAY SUMMARY: This study showed retrospectively that precipitin assays, such as electrosyneresis, could be helpful to distinguish between colonization and infection with Aspergillus fumigatus during the management of severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2) patients in an intensive care unit.

Indexed as

COVID-19Invasive Pulmonary AspergillosisAnimalsAntigens, FungalAspergillusAspergillus fumigatusBiomarkersFemaleMalePrecipitinsRetrospective StudiesSARS-CoV-2Antigens, FungalBiomarkersPrecipitinsAspergillus fumigatuselectrosyneresisprecipitinsSARS-CoV-2somatic antigentracheal aspirates

Identifiers

PMID35604675
PMCPMC9213863
OpenAlexW4226466137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.